EP0091652A1 - Ergoline derivatives, process for producing the ergoline derivatives and pharmaceutical compositions containing them - Google Patents
Ergoline derivatives, process for producing the ergoline derivatives and pharmaceutical compositions containing them Download PDFInfo
- Publication number
- EP0091652A1 EP0091652A1 EP83103352A EP83103352A EP0091652A1 EP 0091652 A1 EP0091652 A1 EP 0091652A1 EP 83103352 A EP83103352 A EP 83103352A EP 83103352 A EP83103352 A EP 83103352A EP 0091652 A1 EP0091652 A1 EP 0091652A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- dimethyl
- pyrimidyl
- carboxamide
- ergoline
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 CC(C1)(*(*)CCC2)[C@@]2(C)c2cccc3c2C1C(N)I=C3 Chemical compound CC(C1)(*(*)CCC2)[C@@]2(C)c2cccc3c2C1C(N)I=C3 0.000 description 3
- HGCIXCUEYOPUTN-UHFFFAOYSA-N C1CC=CCC1 Chemical compound C1CC=CCC1 HGCIXCUEYOPUTN-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D457/00—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid
- C07D457/04—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 8
- C07D457/06—Lysergic acid amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D457/00—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid
- C07D457/02—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid with hydrocarbon or substituted hydrocarbon radicals, attached in position 8
Definitions
- the invention relates to ergoline derivatives, to processes for their preparation, and to pharmaceutical compositions containing them.
- the invention provides ergoline derivatives having the general formula (I) wherein R 1 represents a hydrogen atom or a methyl group, R 2 represents a hydrogen or halogen atom or a methyl group, R 3 represents a hydrogen atom or a methoxy group, R 4 represents a hydrocarbon group having from 1 to 4 carbon atoms; each of X and W independently represents a hydrogen atom, a methyl group, a chlorine atom or a methoxy group, and n is 0,1 or 2 and further provides pharmaceutically acceptable salts of such ergoline derivatives.
- R 1 represents a hydrogen atom or a methyl group
- R 2 represents a hydrogen or halogen atom or a methyl group
- R 3 represents a hydrogen atom or a methoxy group
- R 4 represents a hydrocarbon group having from 1 to 4 carbon atoms
- each of X and W independently represents a hydrogen atom, a methyl group, a chlorine atom or a methoxy group
- n
- the invention also provides a process for the preparation of the ergoline derivatives of the general formula (I) as above defined, which process comprises reacting an activated ester of an ergoline carboxylic acid of the general formula (II), wherein R 1 , R 2 , R 3 , R 4 and n are as above defined, with 4-amino-pyrimidine of the general formula (III), wherein X and W are as above defined, in a solvent, such as tetrahydrofuran, dimethylformamide or dioxan at a temperature of from 50 to 100°C for a period of 24 to 48 hours.
- a solvent such as tetrahydrofuran, dimethylformamide or dioxan
- a suitable activated ester is that prepared by reacting an ergoline acid of formula (II) with 1-hydroxybenzotriazole in the presence of N,N'-dicyclohexylcarbodiimide in tetrahydrofuran at reflux for a period of from 2 to 5 hours.
- the ergoline amides according to the invention are generally isolated by techniques commonly used in chemistry and further purified by crystallization, chromatography or salt formation.
- the ergoline amides according to the invention and their pharmaceutically acceptable salts have been shown to possess a strong--anti'-prolactin activity in rats.
- the prolactin secretion inhibitory action of the compounds has been indirectly evaluated by determining the egg-nidation inhibitory action in rats. For the ergoline derivatives this activity is considered to be correlated with the anti-prolactin activity (E. Fluckiger and E. Del. Pozo, Handb. Exp. Pharmac. 49, 615, 1978), prolactin being the only hypophysial hormone involved in the maintenance of the first part of pregnancy in rats (W. K. Morischige and I. Roth- child, Endocrinology 95, 260, 1974).
- Pregnant Sprague Dowley rats weighing 200 to 250 g were used.
- the compounds to be tested, dissolved in diluted mineral acids, were administered orally to groups from six to eight rats on day 5 of pregnancy.
- the new ergoline derivatives are from 3 to 19 times more active than Bromocryptine as nidation inhibitors. From the above results it is logical to predict that the new ergoline derivatives may find an advantageous clinical exploitation in all the situations in which it is desirable to reduce prolactin levels such as inhibition of puerperal lactation, inhibition of galactorrhoea and treatment of infertility due to hyperprolactinaemia.
- the compounds, for their probable dopamine agonist activity may also find utility, like Bromocryptine, for the treatment of Parkinson's disease and acromegaly. Accordingly, the invention further provides a pharmaceutical composition comprising an ergoline derivative having the general formula (I) as above defined or a pharmaceutically acceptable salt thereof in admixture with a pharmaceutically acceptable diluent or carrier.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
- The invention relates to ergoline derivatives, to processes for their preparation, and to pharmaceutical compositions containing them.
- The invention provides ergoline derivatives having the general formula (I)
- Particularly preferred compounds according to the present invention are indicated as below:
- N-(2',6'-dimethyl-4'-pyrimidyl) -6-methylergoline-8B-carboxamide,
- N-(2',6'-dimethyl-4'-pyrimidyl)-1,6-dimethylergoline-8B-carboxamide,
- N-(4'-pyrimidyl)-6-methylergoline-8B-carboxamide,
- N-(2',6'-dimethyl-4'-pyrimidyl)-2,6-dimethylergoline-8B-carboxamide,
- N-(2',6'-dimethyl-4'-pyrimidyl)-6-propylergoline-8B-carboxamide,
- N-(2',6'-dimethyl-4'-pyrimidyl)-6-allylergoline-8B-carboxamide,
- N-(2',6'-dimethyl-4'-pyrimidyl)-6-isopropylergoline-8B-carboxamide,
- N-(2',6'-dimethyl-4'-pyrimidyl)-1-methyl-6-allyl- ergoline-8B-carboxamide,
- N-(4'-pyrimidyl)-10-methoxy-6-methylergoline-8B-carboxamide,
- N-(2',6'-dimethyl-4'-pyrimidyl)-6-methylergoline-8α-carboxamide,
- N-(2',6'-dimethyl-4'-pyrimidyl)-6-propylergoline-8α-carboxamide,
- 2-(6-methylergolinyl-8B)-N-2',6'-dimethyl-4'-pyrimidinyl-acetamide,
- 3-(6-methylergolinyl-8B)-N-2',6'-dimethyl-4'-pyrimidinyl-propionamide.
- The invention also provides a process for the preparation of the ergoline derivatives of the general formula (I) as above defined, which process comprises reacting an activated ester of an ergoline carboxylic acid of the general formula (II), wherein R1, R2, R3, R4 and n are as above defined, with 4-amino-pyrimidine of the general formula (III), wherein X and W are as above defined,
- The ergoline amides according to the invention are generally isolated by techniques commonly used in chemistry and further purified by crystallization, chromatography or salt formation.
- The ergoline amides according to the invention and their pharmaceutically acceptable salts have been shown to possess a strong--anti'-prolactin activity in rats. The prolactin secretion inhibitory action of the compounds has been indirectly evaluated by determining the egg-nidation inhibitory action in rats. For the ergoline derivatives this activity is considered to be correlated with the anti-prolactin activity (E. Fluckiger and E. Del. Pozo, Handb. Exp. Pharmac. 49, 615, 1978), prolactin being the only hypophysial hormone involved in the maintenance of the first part of pregnancy in rats (W. K. Morischige and I. Roth- child, Endocrinology 95, 260, 1974).
- Pregnant Sprague Dowley rats weighing 200 to 250 g were used. The compounds to be tested, dissolved in diluted mineral acids, were administered orally to groups from six to eight rats on day 5 of pregnancy.
-
- From the table it appears that the new ergoline derivatives are from 3 to 19 times more active than Bromocryptine as nidation inhibitors. From the above results it is logical to predict that the new ergoline derivatives may find an advantageous clinical exploitation in all the situations in which it is desirable to reduce prolactin levels such as inhibition of puerperal lactation, inhibition of galactorrhoea and treatment of infertility due to hyperprolactinaemia. The compounds, for their probable dopamine agonist activity, may also find utility, like Bromocryptine, for the treatment of Parkinson's disease and acromegaly. Accordingly, the invention further provides a pharmaceutical composition comprising an ergoline derivative having the general formula (I) as above defined or a pharmaceutically acceptable salt thereof in admixture with a pharmaceutically acceptable diluent or carrier.
- The following examples illustrate the invention.
- A mixture of 16.2 g of 6-methylergoline-8B-carboxylic acid, 16.2 g of 1-hydroxybenzotriazole and 74.16 g of N,N'-dicyclohexylcarbodiimide in 1800 ml of tetrahydrofuran was refluxed for 4 hours. Then 7.39 g of 4-amino-2,6-dimethylpyrimidine were added and refluxing was continued for 18 hours. The precipitated di- cyclohexyurea was removed by filtration, the filtrate was evaporated to dryness in vacuo and the solid residue was dissolved in chloroform and then extracted with water containing 5 ml of hydrochloric acid. The acid extracts were neutralized with an excess of sodium bicarbonate and then extracted with chloroform. The residue of the organic layer was crystallized from methanol to give 16 g of the title compound, m.p. 258-260°C.
- Operating as in example 1, but employing 1,6-dimethyl- ergoline-8B-carboxylic acid in place of 6-methyl- ergoline-8B-carboxylic acid, the title compounds,m.p. 201-203°C,was obtained in 68 % yield.
- Operating as in example 1, but employing 4-aminopyri- midine in place of 4-amino-2,6-dimethylpyrimidine, the title compound, m.p. 227-229°C, was obtained in 75 % yield.
- Operating as in example 1, but employing 2,6-dimethyl- ergoline-8B-carboxylic acid in place of 6-methylergo- line-8B-carboxylic acid, the title compound, m.p. 152-154°C, was obtained in 72 % yield.
- Operating as in example 1, but employing 6-propyl- ergoline-8B-carboxylic acid in place of.6-methyl- ergoline-8B-carboxylic acid, the title compound, m.p. 120-122°C, was obtained in 65 % yield.
- Operating as in example 1, but employing 6-allyl- ergoline-8B-carboxylic acid in place of 6-methylergo- line-8B-carboxylic acid, the title compound, m.p. 182-186°C, was obtained in 70 % yield.
- Operating as in example 1, but employing 6-isopropyl- ergoline-8B-carboxylic acid in place of 6-methylergo- line-8B-carboxylic acid, the title compound, m.p. 116-118°C, was obtained in 69 % yield.
- Operating as in example 1, but employing 1-methyl-6- allylergoline-8B-carboxylic acid in place of 6-methyl- ergoline-8B-carboxylic acid, the title compound, m.p. 168-170°C, was obtained in 73 % yield.
- Operating as in example 1, but employing 10-methoxy-6-methylergoline-8B-carboxylic acid, the title compound,m.p. 246-247°C, was obtained in 70 % yield.
- Operating as in example 1, but employing 6-methyl- ergoline-8α-carboxylic acid, the title compound, m.p. 258-260°C, was obtained in 71 % yield.
- Operating as in example 1, but employing 6-propyl- ergoline-8α-carboxylic acid, the title compound, m.p. 204-205°C, was obtained in 60 % yield.
- Operating as in example 1, but employing 6-methyl- ergolinyl-8B-acetic acid, the title compound, m.p. 245-247°C, was obtained in 68 % yield.
- Operating as in example 1, but employing 3-(6-methyl- ergolinyl-8B)-propionic acid, the title compound, m.p. 195-196°C, was obtained in 70 % yield.
Claims (13)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AT83103352T ATE18223T1 (en) | 1982-04-13 | 1983-04-06 | ERGOLINE DERIVATIVES, PROCESS FOR THEIR MANUFACTURE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB8210697 | 1982-04-13 | ||
GB8210697 | 1982-04-13 |
Publications (2)
Publication Number | Publication Date |
---|---|
EP0091652A1 true EP0091652A1 (en) | 1983-10-19 |
EP0091652B1 EP0091652B1 (en) | 1986-02-26 |
Family
ID=10529656
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP83103352A Expired EP0091652B1 (en) | 1982-04-13 | 1983-04-06 | Ergoline derivatives, process for producing the ergoline derivatives and pharmaceutical compositions containing them |
Country Status (5)
Country | Link |
---|---|
US (1) | US4632990A (en) |
EP (1) | EP0091652B1 (en) |
JP (1) | JPS58188883A (en) |
AT (1) | ATE18223T1 (en) |
DE (2) | DE3362248D1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2583756A1 (en) * | 1985-06-21 | 1986-12-26 | Richter Gedeon Vegyeszet | PROCESS FOR PREPARING 2-HALO-NICERGOLINE DERIVATIVES AND THEIR ADDITION SALTS WITH ACIDS AND NEW 2-HALONICERGOLINES, COMPOSITIONS COMPRISING 2-HALONICERGOLINES AND PROCESS FOR PREPARING THE SAME |
EP0206206A1 (en) * | 1985-06-19 | 1986-12-30 | FARMITALIA CARLO ERBA S.r.l. | Ergoline derivatives, process for preparing them, pharmaceutical composition and use |
EP0470325A1 (en) * | 1990-08-06 | 1992-02-12 | Maria Francesca Devoto | Composition and method to keep under control the reproduction rate of vertebrate animals by means of a composition containing peripheral dopamine agonists |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1410349A (en) * | 1971-12-10 | 1975-10-15 | Sandoz Ltd | Lysergic acid derivatives |
US3957785A (en) * | 1971-12-02 | 1976-05-18 | Societa' Farmaceutici Italia S.P.A. | Bβ-Pyrimidino-aminomethyl-10α-ergoline and 10α-methoxyergoline derivatives |
GB1512874A (en) * | 1975-04-24 | 1978-06-01 | Richter Gedeon Vegyeszet | Lysergic acid amides and process for preparing same |
EP0070562A1 (en) * | 1981-07-21 | 1983-01-26 | FARMITALIA CARLO ERBA S.p.A. | Ergoline derivatives, processes for their preparation and pharmaceutical compositions containing them |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3238211A (en) * | 1966-03-01 | Derhvatives of g-methyl and i,g-dimethyl ergolhne | ||
CH344731A (en) * | 1956-05-18 | 1960-02-29 | Sandoz Ag | Process for the production of new derivatives of the lysergic acid series alkylated on the indole nitrogen |
FR1339406A (en) * | 1962-11-23 | 1963-10-04 | Farmaceutici Italia | Process for the preparation of novel derivatives of 6-methylergoline pi and 1, 6-dimethylergoline pi |
CH459243A (en) * | 1963-03-26 | 1968-07-15 | Sandoz Ag | Process for the production of new lyser gals |
GB1112909A (en) * | 1964-09-15 | 1968-05-08 | Sandoz Ltd | Ergoline derivatives |
US3966941A (en) * | 1970-09-23 | 1976-06-29 | Spofa United Pharmaceutical Works | Composition for preventing lactation or pregnancy in mammals and the method for using the same |
US4035501A (en) * | 1971-12-10 | 1977-07-12 | Sandoz Ltd. | N-lysergyl-amino-pyridines |
CH578565A5 (en) * | 1972-12-07 | 1976-08-13 | Sandoz Ag | N-(2-amino-5-pyridyl) lysergic acid amides - with saluretic and serotonin antagonist activity |
US3904633A (en) * | 1973-02-05 | 1975-09-09 | Richter Gedeon Vegyeszet | Lysergic amides |
US4147789A (en) * | 1974-03-14 | 1979-04-03 | Sandoz Ltd. | 6-Methyl-8-thiomethyl-ergolene derivatives |
US4054660A (en) * | 1975-04-14 | 1977-10-18 | Eli Lilly And Company | Method of inhibiting prolactin |
US4291031A (en) * | 1979-02-19 | 1981-09-22 | Fujisawa Pharmaceutical Co., Ltd. | 3-Phosphonocephalosporanic acid derivatives, and pharmaceutical composition comprising the same |
GB2058746A (en) * | 1979-09-20 | 1981-04-15 | Erba Farmitalia | 6,7-Secoergolines |
GB2074566B (en) * | 1980-04-03 | 1983-11-02 | Erba Farmitalia | Ergoline derivatives |
-
1983
- 1983-04-06 AT AT83103352T patent/ATE18223T1/en not_active IP Right Cessation
- 1983-04-06 DE DE8383103352T patent/DE3362248D1/en not_active Expired
- 1983-04-06 EP EP83103352A patent/EP0091652B1/en not_active Expired
- 1983-04-06 DE DE198383103352T patent/DE91652T1/en active Pending
- 1983-04-12 JP JP58063092A patent/JPS58188883A/en active Pending
- 1983-04-13 US US06/484,477 patent/US4632990A/en not_active Expired - Fee Related
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3957785A (en) * | 1971-12-02 | 1976-05-18 | Societa' Farmaceutici Italia S.P.A. | Bβ-Pyrimidino-aminomethyl-10α-ergoline and 10α-methoxyergoline derivatives |
GB1410349A (en) * | 1971-12-10 | 1975-10-15 | Sandoz Ltd | Lysergic acid derivatives |
GB1512874A (en) * | 1975-04-24 | 1978-06-01 | Richter Gedeon Vegyeszet | Lysergic acid amides and process for preparing same |
EP0070562A1 (en) * | 1981-07-21 | 1983-01-26 | FARMITALIA CARLO ERBA S.p.A. | Ergoline derivatives, processes for their preparation and pharmaceutical compositions containing them |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0206206A1 (en) * | 1985-06-19 | 1986-12-30 | FARMITALIA CARLO ERBA S.r.l. | Ergoline derivatives, process for preparing them, pharmaceutical composition and use |
US4746666A (en) * | 1985-06-19 | 1988-05-24 | Farmitalia Carlo Erba S.P.A. | Ergoline compounds useful as antiparkinson agents |
FR2583756A1 (en) * | 1985-06-21 | 1986-12-26 | Richter Gedeon Vegyeszet | PROCESS FOR PREPARING 2-HALO-NICERGOLINE DERIVATIVES AND THEIR ADDITION SALTS WITH ACIDS AND NEW 2-HALONICERGOLINES, COMPOSITIONS COMPRISING 2-HALONICERGOLINES AND PROCESS FOR PREPARING THE SAME |
EP0470325A1 (en) * | 1990-08-06 | 1992-02-12 | Maria Francesca Devoto | Composition and method to keep under control the reproduction rate of vertebrate animals by means of a composition containing peripheral dopamine agonists |
Also Published As
Publication number | Publication date |
---|---|
ATE18223T1 (en) | 1986-03-15 |
EP0091652B1 (en) | 1986-02-26 |
JPS58188883A (en) | 1983-11-04 |
US4632990A (en) | 1986-12-30 |
DE3362248D1 (en) | 1986-04-03 |
DE91652T1 (en) | 1984-03-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4526892A (en) | Dimethylaminoalkyl-3-(ergoline-8'βcarbonyl)-ureas | |
CA1290756C (en) | Quinazolinone derivative and processes for preparing the same | |
CA1207766A (en) | Preparation of novel xanthine derivatives | |
US4054660A (en) | Method of inhibiting prolactin | |
EP0070562B1 (en) | Ergoline derivatives, processes for their preparation and pharmaceutical compositions containing them | |
EP0033767B1 (en) | Indolobenzoxazines, processes for preparing and pharmaceutical compositions containing the same | |
US5077298A (en) | Novel 8α-acylaminoergolines | |
US4435408A (en) | Dopaminergic stimulating and antianoxic 4-substituted 2H-indole-2-ones | |
EP0091652B1 (en) | Ergoline derivatives, process for producing the ergoline derivatives and pharmaceutical compositions containing them | |
US4100291A (en) | Novel 1,4-benzodioxanes | |
US3985752A (en) | 6-Methyl-8-(substituted) methylergolines | |
US4791115A (en) | 2,6-dimethyl-8α-pivaloylamino-9,10-didehydro-ergoline | |
US4299836A (en) | Novel ergol-8-ene and ergolin compounds and process for preparing same | |
CA1156648A (en) | Process for preparing ergoline derivatives | |
KR840001473B1 (en) | Process for preparing ergoline derivatives | |
US4782063A (en) | Ergoline esters useful as serotonin antagonists | |
US4681881A (en) | 5-alkoxy-pyrido[4,3-d]pyrimidine derivatives | |
US4196288A (en) | Ergoline derivatives and a process for their preparation | |
GB2074566A (en) | Ergoline Derivatives | |
US4746666A (en) | Ergoline compounds useful as antiparkinson agents | |
US4591597A (en) | Antidiabetic iminosulphonamides | |
US4335135A (en) | 5 Amino-3,4,5,6 tetrahydro-1H-[-6-]cyclohept[c,d]indolols and a method for their use as hypotensives | |
US4835159A (en) | Ergoline esters useful as serotonin antagonists | |
JPH0778062B2 (en) | D-nor-7-ergoline derivative, process for its production, pharmaceutical composition and use | |
PL98288B1 (en) | METHOD OF MAKING D-2-SUBSTITUTE-6-ALKYL-8-SUBSTITUTE ERGOLINE |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
AK | Designated contracting states |
Designated state(s): AT BE CH DE FR GB IT LI NL SE |
|
ITCL | It: translation for ep claims filed |
Representative=s name: ING. A. GIAMBROCONO & C. S.R.L. |
|
TCAT | At: translation of patent claims filed | ||
EL | Fr: translation of claims filed | ||
17P | Request for examination filed |
Effective date: 19831221 |
|
TCNL | Nl: translation of patent claims filed | ||
DET | De: translation of patent claims | ||
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Designated state(s): AT BE CH DE FR GB IT LI NL SE |
|
REF | Corresponds to: |
Ref document number: 18223 Country of ref document: AT Date of ref document: 19860315 Kind code of ref document: T |
|
ITF | It: translation for a ep patent filed |
Owner name: ING. A. GIAMBROCONO & C. S.R.L. |
|
REF | Corresponds to: |
Ref document number: 3362248 Country of ref document: DE Date of ref document: 19860403 |
|
ET | Fr: translation filed | ||
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed | ||
ITPR | It: changes in ownership of a european patent |
Owner name: CAMBIO RAGIONE SOCIALE;FARMITALIA CARLO ERBA S.R.L |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PFA Free format text: FARMITALIA CARLO ERBA S.R.L. |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: 732 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: TP |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: SE Payment date: 19890221 Year of fee payment: 7 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: BE Payment date: 19890222 Year of fee payment: 7 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 19890317 Year of fee payment: 7 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CH Payment date: 19890407 Year of fee payment: 7 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 19890420 Year of fee payment: 7 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: AT Payment date: 19890428 Year of fee payment: 7 |
|
ITTA | It: last paid annual fee | ||
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 19890430 Year of fee payment: 7 Ref country code: GB Payment date: 19890430 Year of fee payment: 7 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Effective date: 19900406 Ref country code: AT Effective date: 19900406 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Effective date: 19900407 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LI Effective date: 19900430 Ref country code: CH Effective date: 19900430 Ref country code: BE Effective date: 19900430 |
|
BERE | Be: lapsed |
Owner name: FARMITALIA CARLO ERBA S.P.A. Effective date: 19900430 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Effective date: 19901101 |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee | ||
NLV4 | Nl: lapsed or anulled due to non-payment of the annual fee | ||
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FR Effective date: 19901228 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DE Effective date: 19910101 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST |
|
EUG | Se: european patent has lapsed |
Ref document number: 83103352.7 Effective date: 19910115 |